Corbus Pharmaceuticals: Data Update And Fundraising Efforts Do Not Diminish The Thesis

Core Insights - Corbus Pharmaceuticals (CRBP) was initially valued at around $100, leading to a favorable investment thesis for the company [1] Company Analysis - The company operates in the biotech sector, with a focus on clinical trials and drug development [1] - The author has a PhD in biochemistry and extensive experience in analyzing biotech companies, indicating a strong foundation for evaluating the company's potential [1] Investment Perspective - The article emphasizes the importance of understanding the science behind biotech investments to avoid pitfalls [1]